PRDM1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using PRDM1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

**Background of PRDM1 Antibody**

The PRDM1 (PR Domain Zinc Finger Protein 1) gene encodes BLIMP1. a transcriptional repressor critical for terminal differentiation of B lymphocytes into plasma cells and regulation of immune responses. PRDM1/BLIMP1 suppresses gene networks that maintain B-cell proliferation, enabling cells to exit the cell cycle and adopt a secretory phenotype. It also modulates T-cell function and interferon signaling, highlighting its role in immune homeostasis.

PRDM1 antibodies are essential tools in studying its expression, localization, and function in normal and pathological contexts. Dysregulation of PRDM1 is linked to cancers (e.g., B-cell lymphomas, Hodgkin’s lymphoma, colorectal cancer), autoimmune diseases, and viral infections (e.g., HIV). Antibodies targeting PRDM1 are used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to assess protein levels in tissues or cell lines, aiding in disease mechanism research and biomarker discovery.

Commercial PRDM1 antibodies are typically raised against specific epitopes (e.g., N-terminal or C-terminal regions) and validated for species reactivity (human, mouse, rat). Clone specificity (e.g., clone 3H2-E8) and applications vary, requiring careful selection based on experimental needs. Aberrant PRDM1 expression, due to mutations or epigenetic silencing, correlates with poor prognosis in malignancies, making these antibodies valuable in both basic research and clinical diagnostics. Recent studies also explore PRDM1’s role in immunotherapy resistance, emphasizing its therapeutic relevance.